Table 1.
Estimates of progression-free survival (PFS) and overall survival (OS) in patients with different changes in BRAFV600E under first-line treatment
| BRAFV600E | No. | Events | mPFS, 95% CI (months) |
HR | P* | Events | mOS, 95% CI (months) |
HR | P* |
| Remained MUT |
5 | 5 | 6.4, 3.2 to NR | ref | 0.002 | 3 | 11.4, 5.6 to NR | ref | 0.022 |
| Clearance | 5 | 2 | NR, 18.9 to NR | 0.07 | 2 | NR, 20.8 to NR | 0.09 | ||
| Remained WT |
134 | 97 | 11.5, 10.4 to 13.3 | ref | 0.179 | 55 | 26.7, 22.7 to NR | ref | 0.996 |
| Acquisition | 1 | 1 | 8.7, NR to NR | 3.95 | 0 | NR, NR to NR | <0.01 |
*Statistical significance was determined by Wald test of the multivariable Cox models. The change in the ctDNA fraction of cfDNA, estimated by MSAF, was included as a variable.
mOS, median overall survival; mPFS, median progression-free survival; MUT, mutant; NR, not reached; ref, reference; WT, wild-type.